| Name | Title | Contact Details |
|---|
Advanced O&P Solutions is a Hickory Hills, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Memorial Hospital of Rhode Island is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Memorial Hospital of Rhode Island is based in Pawtucket, RI. You can find more information on Memorial Hospital of Rhode Island at www.mhri.org
Masimo Corporation is a global medical technology company that develops, manufactures and markets non-invasive patient monitoring products.
Healthcare industry veterans Joe Caruncho – whose success at the helm of Preferred Care Partners led to annual sales in excess of $750 million – and Orlando Lopez-Fernandez, Jr., MD, founded Genuine Health Group to usher in a new era of healthcare delivery focused on value instead of volume. Today, Genuine Health is building a model for managing care delivery that embodies traditional values, promises reliability, and embraces flexibility and technology. Through its accountable care organization, PremierMD ACO, the company aims to improve healthcare outcomes, achieve cost savings for the care of patients who receive traditional, fee-for-service Medicare benefits, and serve as a single point of contact to move doctors` Medicare members into value-based care. And, through its management service organization (MSO), the company aims to deliver financial upside for its participating physicians whose patients are enrolled in Medicare Advantage plans. For both traditional Medicare beneficiaries and those who choose managed care plans, Genuine Health and its providers are demonstrating the powerful effects of value-based care.
Xenon Pharmaceuticals (NASDAQ:XENE) – a biopharmaceutical company with operations in Vancouver, BC, Canada and Boston, MA, U.S.A. – is committed to delivering innovative medicines to provide a brighter future for patients suffering from neurological disorders. At Xenon, we are advancing an exciting pipeline of neurology-focused therapies, with a particular emphasis on novel treatments for both adult and pediatric patients with epilepsy. XEN496 is currently being evaluated in the Phase 3 “EPIK” clinical trial in young patients with KCNQ2-DEE, a rare and severe form of childhood epilepsy. Late-stage development plans are also underway for our XEN1101 program, building upon the compelling data from the Phase 2b “X-TOLE” study in adult patients with focal epilepsy. We are also proud of the leading-edge science coming out of our discovery labs, with many early-stage research programs underway. In addition to Xenon`s proprietary programs, we have ongoing collaborations with our valued pharmaceutical partners. With a healthy balance sheet to support our growth plans, we continue to build a fully-integrated, premier neuroscience company with strong discovery, development, and commercial operations. Our employees are smart, passionate, dedicated, and driven by their incredibly important work to discover, develop, and deliver new medicines for patients in need. Building and maintaining a respectful, collaborative, inclusive, and productive culture is a priority for us. We are looking for great people who thrive in a fast-paced, dynamic work environment to join our team during this transformative time for Xenon.